4.7 Article

Plasma levels of myeloperoxidase are not elevated in patients with stable coronary artery disease

Journal

CLINICA CHIMICA ACTA
Volume 394, Issue 1-2, Pages 59-62

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.cca.2008.04.001

Keywords

cardiovascular diseases; risk factors; myeloperoxidase; polymorphonuclear neutrophils

Funding

  1. NHLBI NIH HHS [R01 HL062705, R01 HL062705-04, HL 62705] Funding Source: Medline

Ask authors/readers for more resources

Background: Plasma and serum levels of myeloperoxidase (MPO), a redox-active hemoprotein released by polymorphonuclear neutrophils (PMN) upon activation, is now recognized as a powerful prognostic determinant of myocardial infarction in patients suffering acute coronary syndromes. However, there is limited information on whether systemic MPO levels are also elevated and of discriminating value in patients with stable coronary artery disease (CAD) representing different ethnic groups. Methods: Plasma levels of MPO and traditional CAD risk factors were quantified in African American and Caucasian patients (n = 557) undergoing elective coronary angiography. Results: MPO levels did not differ significantly between patients with or without CAD 1421 pM (321, 533) vs. 412 pM (326, 500). p>0.05]. MPO levels were similar across ethnicity and gender, and correlated positively with CRP and fibrinogen levels (r=0.132, p=0.002 and r=0.106, p=0.011, respectively). Conclusion: In conclusion, plasma MPO levels were not elevated in patients with stable CAD, suggesting that systemic release of MPO is not a characteristic feature of asymptomatic CAD. (C) 2008 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available